Bone Marrow Transplant Market Trend & Forecast by 2033

Q: How Much of The Market Is Accounted for By the United States?

Potentially holding 32.3% of the market in North America. Read Report

Q: What is The Market Share of Europe?

The market has been dominated by Europe, 53.1%. Read Report

Bone Marrow Transplant Market Outlook

The bone marrow transplant market is anticipated to flourish at an average CAGR of 3.4% between 2023 and 2033. The market is expected to hold a market share of US$ 14.86 billion by 2033, while the market is likely to reach a value of US$ 10.65 billion in 2023. A historical CAGR of 2.5% has been recorded by the experts of Future Market Insights for the market concerned.

The hematopoietic stem cell is a soft vascular tissue in the interiors of long bones, and a bone marrow transplant is identified as the procedure to replace the damaged or destroyed bone marrow with healthy bone marrow stem cells.

Attributes	Details
Bone Marrow Transplant Market CAGR (2023 to 2033)	3.4%
Bone Marrow Transplant Market Size (2023)	US$ 10.65 billion
Bone Marrow Transplant Market Size (2033)	US$ 14.86 billion

The bone marrow transplant procedure is prescribed for the treatment of advanced stages of leukemia, Hodgkin, and non-Hodgkin lymphomas, multiple myeloma, aplastic and sickle cell anemia, thalassemia, and other diseases. Increasing awareness, combined with an increase in initiatives run by healthcare practitioners, is majorly responsible for the global growth of the market.

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

Market Scenario Analysis Potential Drivers and Restraints

The market is anticipated to have mixed dynamics contributing to the bearish propulsion of the bone marrow transplant market. Several factors impacting the expansion of the market are identified during the study.

Besides the factors influencing growth, it is also identified that certain aspects can limit growth and curb the pace of growth further in the market.

Drivers:

The key factor affecting the bone marrow transplant industry is the surge in the prevalence of blood cancer and other blood-related diseases. The statistics predicted by the experts of FMI are anticipated to help the forum propel over the forecast period.
The growing incidences of non-Hodgkin and Hodgkin lymphoma, thalassemia, and leukemia, along with the common bone marrow diseases around the world, the developments in technology, and the enhancement of the healthcare infrastructure are likely to drive the market in the long run.
A steep increase in the development of stem cell cryopreservation, identified as the need of the hour, is majorly contributing to the bone marrow transplant market and is likely to gain further traction in the upcoming years.
An increase in research and development activities is projected to boost the market, and new products are being launched that may help the industry flourish over the forecast period.
A rise in funding for logistic services and growing per capita healthcare expenses are expected to propel the market's growth.

Restraints:

It is identified that there is a high expenditure associated with the treatment, and the high cost of bone marrow transplant is likely to serve as a deterring factor for the bone marrow transplant market, as a large section of the populace cannot afford such expensive treatment of the diseases.
There is a shortage of bone marrow donors, which is an aspect responsible for the impeding growth of the bone marrow transplant market in the near future.
The lack of reimbursement policies for organ transplantation procedures in emerging economies and developed countries is expected to hamper the growth of the industry during the period.

Country-wise Insights

Country	Revenue Share % (2022)
United States	30.3%
Germany	11.9%
Japan	2/0%
North America	32.3%
Europe	53.1%

Country	CAGR % (2023 to 2033)
China	4.2%
India	3.4%
United Kingdom	2.4%
Australia	3.1%

Overview of the North America Bone Marrow Transplant Market

North America is projected to secure steady bone marrow transplant market growth during the forecast period. The region cumulatively held 32.3% market share of the global bone marrow transplant market in 2022.

The factors attributing to the growth can be mentioned as follows:

There is a growth in the healthcare infrastructure of North America; capital expenditures are initiated by the key players prevailing in this region, coupled with an installed base for different kinds of products for the bone marrow transplant market.
It is anticipated that the North American region is having favorable regulatory scenarios that are likely to impact the bone marrow transplant market positively.

European Region Bolstering the Global Bone Marrow Transplant Market

Europe is projected to dominate the global market for bone marrow transplants during the forecast period. At present, Europe holds 53.1% of the total market share for bone marrow transplants worldwide in 2022.

The reasons owing for such extensive market expansion are mentioned below:

The increasing geriatric population of Europe is widely driving the bone marrow transplant market as they are more prone to severe diseases.
The innovative healthcare systems have introduced bone marrow transplants in their contributions and the state-of-the-art public facilities, which may further boost the growth of the bone marrow transplant market in the region during the forecast period.
New technology penetration in Europe is another factor boosting the concerned market of the region.

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

Categorical Analysis

Category	By Transplant Type
Leading Segment	Autologous
Market Share (2022)	54.5%

Category	By End User
Leading Segment	Hospital
Market Share (2022)	90.3%

Start-up Ecosystem

The start-ups in the bone marrow transplant market are indulging in collaborations and continually making innovations to stem cell transplant procedures to further make it convenient and cost-efficient for the population.

Company Name	Magenta Therapeutics, Cambridge (United States)
Total Funding	US$ 151 million
Description	Developed stem cell-based therapies for autoimmune disease, genetic blood disorders, and cancer. The company has developed stem cell transplants by using targeted antibodies, stem cell harvesting using new biologic agents, and increasing stem cell numbers by targeting self-renewal pathways.

Company Name	Kiadis Pharma, Amsterdam (Netherlands)
Total Funding	US$ 33 million
Description	Kiadis Pharma is a developer of therapeutic solutions for hematopoietic stem cell transplants. It is focused on developing solutions for complications and limitations of hematopoietic stem cell transplants (HSCT) in blood cancer patients. The company uses all depleted T-cell immunotherapeutics (ATIR) to support the patient’s newly transplanted immune system before it becomes fully functional. This enables better acceptance of even haploidentical (or lower) stem cell donors. Kiadis is investigating the use of ATIR in leukemia and thalassemia.

Company Name	Talaris, Boston
Total Funding	US$ 215 million
Description	Talaris Therapeutics is involved in developing single-dose cell therapy to treat living donor kidney transplant tolerance. They have developed a proprietary technology that allows candidates for bone marrow transplants to receive hematopoietic stem cells (HSCs). The lead candidate, FCR001, is in phase III clinical trial, which is being investigated for living donor kidney transplant tolerance.

Competitive Landscape

The bone marrow transplant market is highly competitive and consists of several leading players. To increase their global market presence, market leaders are engaging in various product launches, mergers and acquisitions, and development activities focusing on orthopedic surgical treatments.

Recent Developments

Some Recent Developments Identified in the Analysis are:

In May 2020, Gamida Cell Ltd., an advanced cell therapy company committed to finding cures for blood cancer and serious blood diseases, declared positive topline results from its Phase 3 clinical study evaluating the safety and efficacy of omidubicel, investigational advanced cell therapy in development as a potentially life-saving treatment option for patients in need of bone marrow transplant.
In November 2019, Lonza Group Ltd. partnered with Cryoport, Inc. in the cell and gene therapy field and across Lonza's 'vein-to-vein' delivery network.
In September 2017, Inotek Pharmaceuticals entered into a definitive merger agreement with Rocket Pharmaceuticals, a United States-based gene therapy company.

Key Players

Merck Millipore Corporation
Sanofi-Aventis LLC.
AllCells LLC.
STEMCELL Technologies
ATCC Inc.
Hemacare Corporation
Cellular Dynamics International
ReachBio LLC.
Conversant Bio ABM Inc.
PromoCell GmbH
Cruline Human biospecimen PRO
Lifeline Cell Technology
Mesoblast Ltd.

Key Segments Covered

By Transplant Type:

Autologous
Allogeneic

By Disease Indication:

Leukemia
Lymphoma
Myeloma
Others (anemia, thalassemia, etc.)

By End User:

Hospitals
Multispecialty Clinics
Ambulatory Surgical Centers
Others

Key Regions Covered:

North America
- United States
- Canada
Latin America
- Brazil
- Mexico
- Rest of Latin America
Europe
- Germany
- United Kingdom
- France
- Spain
- Russia
- Rest of Europe
Japan
Asia Pacific Excluding Japan
- China
- India
- Malaysia
- Singapore
- Australia
- Rest of Asia Pacific Excluding Japan (APEJ)
The Middle East and Africa
- GCC Countries
- Israel
- South Africa
- Middle East and Africa (MEA)

Frequently Asked Questions

How Significant Is the Current Market?

The market is anticipated to be valued at US$ 10.65 billion in 2023.

How Has the Market Developed in The Past?

The global market advanced at a 2.5% HCAGR from 2018 to 2022.

What Is the Projected Market Growth Between 2023 And 2033?

Up until 2033, the market is anticipated to thrive at a CAGR of 3.4%.

How Much of The Market Is Accounted for By the United States?

Potentially holding 32.3% of the market in North America.

What is The Market Share of Europe?

The market has been dominated by Europe, 53.1%.

What Will the Market Be Worth In 2033?

By 2033, the market is anticipated to be worth US$14.86 billion.

What Is the Prominent Transplant Type on The Market?

The autologous category to escalate to a market share of 54.5% in 2023.

Table of Content

1. Executive Summary
    1.1. Global Market Outlook
    1.2. Demand-side Trends
    1.3. Supply-side Trends
    1.4. Technology Roadmap Analysis
    1.5. Analysis and Recommendations
2. Market Overview
    2.1. Market Coverage / Taxonomy
    2.2. Market Definition / Scope / Limitations
3. Market Background
    3.1. Market Dynamics
        3.1.1. Drivers
        3.1.2. Restraints
        3.1.3. Opportunity
        3.1.4. Trends
    3.2. Scenario Forecast
        3.2.1. Demand in Optimistic Scenario
        3.2.2. Demand in Likely Scenario
        3.2.3. Demand in Conservative Scenario
    3.3. Opportunity Map Analysis
    3.4. Investment Feasibility Matrix
    3.5. PESTLE and Porter’s Analysis
    3.6. Regulatory Landscape
        3.6.1. By Key Regions
        3.6.2. By Key Countries
    3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
    4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
        4.2.1. Y-o-Y Growth Trend Analysis
        4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Transplant Type
    5.1. Introduction / Key Findings
    5.2. Historical Market Size Value (US$ Million) Analysis By Transplant Type, 2018 to 2022
    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Transplant Type, 2023 to 2033
        5.3.1. Autologous
        5.3.2. Allogeneic
    5.4. Y-o-Y Growth Trend Analysis By Transplant Type, 2018 to 2022
    5.5. Absolute $ Opportunity Analysis By Transplant Type, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Disease Indication
    6.1. Introduction / Key Findings
    6.2. Historical Market Size Value (US$ Million) Analysis By Disease Indication, 2018 to 2022
    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Disease Indication, 2023 to 2033
        6.3.1. Leukemia
        6.3.2. Lymphoma
        6.3.3. Myeloma
        6.3.4. Others
    6.4. Y-o-Y Growth Trend Analysis By Disease Indication, 2018 to 2022
    6.5. Absolute $ Opportunity Analysis By Disease Indication, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-User
    7.1. Introduction / Key Findings
    7.2. Historical Market Size Value (US$ Million) Analysis By End-User , 2018 to 2022
    7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End-User , 2023 to 2033
        7.3.1. Hospitals
        7.3.2. Multispecialty Clinics
        7.3.3. Ambulatory Surgical Centers
        7.3.4. Others
    7.4. Y-o-Y Growth Trend Analysis By End-User , 2018 to 2022
    7.5. Absolute $ Opportunity Analysis By End-User , 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
    8.1. Introduction
    8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
    8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
        8.3.1. North America
        8.3.2. Latin America
        8.3.3. Western Europe
        8.3.4. Eastern Europe
        8.3.5. South Asia and Pacific
        8.3.6. East Asia
        8.3.7. Middle East and Africa
    8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        9.2.1. By Country
            9.2.1.1. USA.
            9.2.1.2. Canada
        9.2.2. By Transplant Type
        9.2.3. By Disease Indication
        9.2.4. By End-User
    9.3. Market Attractiveness Analysis
        9.3.1. By Country
        9.3.2. By Transplant Type
        9.3.3. By Disease Indication
        9.3.4. By End-User
    9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        10.2.1. By Country
            10.2.1.1. Brazil
            10.2.1.2. Mexico
            10.2.1.3. Rest of Latin America
        10.2.2. By Transplant Type
        10.2.3. By Disease Indication
        10.2.4. By End-User
    10.3. Market Attractiveness Analysis
        10.3.1. By Country
        10.3.2. By Transplant Type
        10.3.3. By Disease Indication
        10.3.4. By End-User
    10.4. Key Takeaways
11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        11.2.1. By Country
            11.2.1.1. Germany
            11.2.1.2. United Kingdom.
            11.2.1.3. France
            11.2.1.4. Spain
            11.2.1.5. Italy
            11.2.1.6. Rest of Western Europe
        11.2.2. By Transplant Type
        11.2.3. By Disease Indication
        11.2.4. By End-User
    11.3. Market Attractiveness Analysis
        11.3.1. By Country
        11.3.2. By Transplant Type
        11.3.3. By Disease Indication
        11.3.4. By End-User
    11.4. Key Takeaways
12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        12.2.1. By Country
            12.2.1.1. Poland
            12.2.1.2. Russia
            12.2.1.3. Czech Republic
            12.2.1.4. Romania
            12.2.1.5. Rest of Eastern Europe
        12.2.2. By Transplant Type
        12.2.3. By Disease Indication
        12.2.4. By End-User
    12.3. Market Attractiveness Analysis
        12.3.1. By Country
        12.3.2. By Transplant Type
        12.3.3. By Disease Indication
        12.3.4. By End-User
    12.4. Key Takeaways
13. South Asia and Pacific Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        13.2.1. By Country
            13.2.1.1. India
            13.2.1.2. Bangladesh
            13.2.1.3. Australia
            13.2.1.4. New Zealand
            13.2.1.5. Rest of South Asia and Pacific
        13.2.2. By Transplant Type
        13.2.3. By Disease Indication
        13.2.4. By End-User
    13.3. Market Attractiveness Analysis
        13.3.1. By Country
        13.3.2. By Transplant Type
        13.3.3. By Disease Indication
        13.3.4. By End-User
    13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        14.2.1. By Country
            14.2.1.1. China
            14.2.1.2. Japan
            14.2.1.3. South Korea
        14.2.2. By Transplant Type
        14.2.3. By Disease Indication
        14.2.4. By End-User
    14.3. Market Attractiveness Analysis
        14.3.1. By Country
        14.3.2. By Transplant Type
        14.3.3. By Disease Indication
        14.3.4. By End-User
    14.4. Key Takeaways
15. Middle East and Africa Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
    15.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
    15.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
        15.2.1. By Country
            15.2.1.1. GCC Countries
            15.2.1.2. South Africa
            15.2.1.3. Israel
            15.2.1.4. Rest of MEA
        15.2.2. By Transplant Type
        15.2.3. By Disease Indication
        15.2.4. By End-User
    15.3. Market Attractiveness Analysis
        15.3.1. By Country
        15.3.2. By Transplant Type
        15.3.3. By Disease Indication
        15.3.4. By End-User
    15.4. Key Takeaways
16. Key Countries Market Analysis
    16.1. USA.
        16.1.1. Pricing Analysis
        16.1.2. Market Share Analysis, 2022
            16.1.2.1. By Transplant Type
            16.1.2.2. By Disease Indication
            16.1.2.3. By End-User
    16.2. Canada
        16.2.1. Pricing Analysis
        16.2.2. Market Share Analysis, 2022
            16.2.2.1. By Transplant Type
            16.2.2.2. By Disease Indication
            16.2.2.3. By End-User
    16.3. Brazil
        16.3.1. Pricing Analysis
        16.3.2. Market Share Analysis, 2022
            16.3.2.1. By Transplant Type
            16.3.2.2. By Disease Indication
            16.3.2.3. By End-User
    16.4. Mexico
        16.4.1. Pricing Analysis
        16.4.2. Market Share Analysis, 2022
            16.4.2.1. By Transplant Type
            16.4.2.2. By Disease Indication
            16.4.2.3. By End-User
    16.5. Germany
        16.5.1. Pricing Analysis
        16.5.2. Market Share Analysis, 2022
            16.5.2.1. By Transplant Type
            16.5.2.2. By Disease Indication
            16.5.2.3. By End-User
    16.6. United Kingdom.
        16.6.1. Pricing Analysis
        16.6.2. Market Share Analysis, 2022
            16.6.2.1. By Transplant Type
            16.6.2.2. By Disease Indication
            16.6.2.3. By End-User
    16.7. France
        16.7.1. Pricing Analysis
        16.7.2. Market Share Analysis, 2022
            16.7.2.1. By Transplant Type
            16.7.2.2. By Disease Indication
            16.7.2.3. By End-User
    16.8. Spain
        16.8.1. Pricing Analysis
        16.8.2. Market Share Analysis, 2022
            16.8.2.1. By Transplant Type
            16.8.2.2. By Disease Indication
            16.8.2.3. By End-User
    16.9. Italy
        16.9.1. Pricing Analysis
        16.9.2. Market Share Analysis, 2022
            16.9.2.1. By Transplant Type
            16.9.2.2. By Disease Indication
            16.9.2.3. By End-User
    16.10. Poland
        16.10.1. Pricing Analysis
        16.10.2. Market Share Analysis, 2022
            16.10.2.1. By Transplant Type
            16.10.2.2. By Disease Indication
            16.10.2.3. By End-User
    16.11. Russia
        16.11.1. Pricing Analysis
        16.11.2. Market Share Analysis, 2022
            16.11.2.1. By Transplant Type
            16.11.2.2. By Disease Indication
            16.11.2.3. By End-User
    16.12. Czech Republic
        16.12.1. Pricing Analysis
        16.12.2. Market Share Analysis, 2022
            16.12.2.1. By Transplant Type
            16.12.2.2. By Disease Indication
            16.12.2.3. By End-User
    16.13. Romania
        16.13.1. Pricing Analysis
        16.13.2. Market Share Analysis, 2022
            16.13.2.1. By Transplant Type
            16.13.2.2. By Disease Indication
            16.13.2.3. By End-User
    16.14. India
        16.14.1. Pricing Analysis
        16.14.2. Market Share Analysis, 2022
            16.14.2.1. By Transplant Type
            16.14.2.2. By Disease Indication
            16.14.2.3. By End-User
    16.15. Bangladesh
        16.15.1. Pricing Analysis
        16.15.2. Market Share Analysis, 2022
            16.15.2.1. By Transplant Type
            16.15.2.2. By Disease Indication
            16.15.2.3. By End-User
    16.16. Australia
        16.16.1. Pricing Analysis
        16.16.2. Market Share Analysis, 2022
            16.16.2.1. By Transplant Type
            16.16.2.2. By Disease Indication
            16.16.2.3. By End-User
    16.17. New Zealand
        16.17.1. Pricing Analysis
        16.17.2. Market Share Analysis, 2022
            16.17.2.1. By Transplant Type
            16.17.2.2. By Disease Indication
            16.17.2.3. By End-User
    16.18. China
        16.18.1. Pricing Analysis
        16.18.2. Market Share Analysis, 2022
            16.18.2.1. By Transplant Type
            16.18.2.2. By Disease Indication
            16.18.2.3. By End-User
    16.19. Japan
        16.19.1. Pricing Analysis
        16.19.2. Market Share Analysis, 2022
            16.19.2.1. By Transplant Type
            16.19.2.2. By Disease Indication
            16.19.2.3. By End-User
    16.20. South Korea
        16.20.1. Pricing Analysis
        16.20.2. Market Share Analysis, 2022
            16.20.2.1. By Transplant Type
            16.20.2.2. By Disease Indication
            16.20.2.3. By End-User
    16.21. GCC Countries
        16.21.1. Pricing Analysis
        16.21.2. Market Share Analysis, 2022
            16.21.2.1. By Transplant Type
            16.21.2.2. By Disease Indication
            16.21.2.3. By End-User
    16.22. South Africa
        16.22.1. Pricing Analysis
        16.22.2. Market Share Analysis, 2022
            16.22.2.1. By Transplant Type
            16.22.2.2. By Disease Indication
            16.22.2.3. By End-User
    16.23. Israel
        16.23.1. Pricing Analysis
        16.23.2. Market Share Analysis, 2022
            16.23.2.1. By Transplant Type
            16.23.2.2. By Disease Indication
            16.23.2.3. By End-User
17. Market Structure Analysis
    17.1. Competition Dashboard
    17.2. Competition Benchmarking
    17.3. Market Share Analysis of Top Players
        17.3.1. By Regional
        17.3.2. By Transplant Type
        17.3.3. By Disease Indication
        17.3.4. By End-User
18. Competition Analysis
    18.1. Competition Deep Dive
        18.1.1. Lonza Group Ltd.
            18.1.1.1. Overview
            18.1.1.2. Product Portfolio
            18.1.1.3. Profitability by Market Segments
            18.1.1.4. Sales Footprint
            18.1.1.5. Strategy Overview
                18.1.1.5.1. Marketing Strategy
        18.1.2. Merck Millipore Corporation
            18.1.2.1. Overview
            18.1.2.2. Product Portfolio
            18.1.2.3. Profitability by Market Segments
            18.1.2.4. Sales Footprint
            18.1.2.5. Strategy Overview
                18.1.2.5.1. Marketing Strategy
        18.1.3. Sanofi-Aventis LLC.
            18.1.3.1. Overview
            18.1.3.2. Product Portfolio
            18.1.3.3. Profitability by Market Segments
            18.1.3.4. Sales Footprint
            18.1.3.5. Strategy Overview
                18.1.3.5.1. Marketing Strategy
        18.1.4. AllCells LLC.
            18.1.4.1. Overview
            18.1.4.2. Product Portfolio
            18.1.4.3. Profitability by Market Segments
            18.1.4.4. Sales Footprint
            18.1.4.5. Strategy Overview
                18.1.4.5.1. Marketing Strategy
        18.1.5. STEMCELL Technologies
            18.1.5.1. Overview
            18.1.5.2. Product Portfolio
            18.1.5.3. Profitability by Market Segments
            18.1.5.4. Sales Footprint
            18.1.5.5. Strategy Overview
                18.1.5.5.1. Marketing Strategy
        18.1.6. ATCC Inc.
            18.1.6.1. Overview
            18.1.6.2. Product Portfolio
            18.1.6.3. Profitability by Market Segments
            18.1.6.4. Sales Footprint
            18.1.6.5. Strategy Overview
                18.1.6.5.1. Marketing Strategy
        18.1.7. Hemacare Corporation
            18.1.7.1. Overview
            18.1.7.2. Product Portfolio
            18.1.7.3. Profitability by Market Segments
            18.1.7.4. Sales Footprint
            18.1.7.5. Strategy Overview
                18.1.7.5.1. Marketing Strategy
        18.1.8. Cellular Dynamics International
            18.1.8.1. Overview
            18.1.8.2. Product Portfolio
            18.1.8.3. Profitability by Market Segments
            18.1.8.4. Sales Footprint
            18.1.8.5. Strategy Overview
                18.1.8.5.1. Marketing Strategy
        18.1.9. ReachBio LLC.
            18.1.9.1. Overview
            18.1.9.2. Product Portfolio
            18.1.9.3. Profitability by Market Segments
            18.1.9.4. Sales Footprint
            18.1.9.5. Strategy Overview
                18.1.9.5.1. Marketing Strategy
        18.1.10. Conversant Bio, ABM Inc.
            18.1.10.1. Overview
            18.1.10.2. Product Portfolio
            18.1.10.3. Profitability by Market Segments
            18.1.10.4. Sales Footprint
            18.1.10.5. Strategy Overview
                18.1.10.5.1. Marketing Strategy
        18.1.11. PromoCell GmbH
            18.1.11.1. Overview
            18.1.11.2. Product Portfolio
            18.1.11.3. Profitability by Market Segments
            18.1.11.4. Sales Footprint
            18.1.11.5. Strategy Overview
                18.1.11.5.1. Marketing Strategy
        18.1.12. Cruline Human biospecimen PRO
            18.1.12.1. Overview
            18.1.12.2. Product Portfolio
            18.1.12.3. Profitability by Market Segments
            18.1.12.4. Sales Footprint
            18.1.12.5. Strategy Overview
                18.1.12.5.1. Marketing Strategy
        18.1.13. Lifeline Cell Technology
            18.1.13.1. Overview
            18.1.13.2. Product Portfolio
            18.1.13.3. Profitability by Market Segments
            18.1.13.4. Sales Footprint
            18.1.13.5. Strategy Overview
                18.1.13.5.1. Marketing Strategy
        18.1.14. Mesoblast Ltd.
            18.1.14.1. Overview
            18.1.14.2. Product Portfolio
            18.1.14.3. Profitability by Market Segments
            18.1.14.4. Sales Footprint
            18.1.14.5. Strategy Overview
                18.1.14.5.1. Marketing Strategy
19. Assumptions & Acronyms Used
20. Research Methodology

Bone Marrow Transplant Market

Bone Marrow Transplant Market Analysis by Autologous and Allogeneic Transplant Type